Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Intravenous daratumumab is approved for the treatment of multiple myeloma. In part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and an efficacy simil...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: San-Miguel, Jesus, Usmani, Saad Z., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Liu, Kevin, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L., Luo, Man, Farnsworth, Andrew, Nahi, Hareth, Chari, Ajai
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168515/
https://ncbi.nlm.nih.gov/pubmed/32354874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.243790
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados